Significats de anastrozole en anglès

Objectives: We aimed to determine the safety and efficacy of anastrozole in PAH.

Larger and longer phase II clinical trials of anastrozole may be warranted in patients with PAH.

Here we report a pharmacokinetic subset analysis investigating a possible drug interaction between anastrozole and fulvestrant.

None of the three biomarkers identified a set of patients with differential benefit from anastrozole over tamoxifen.

Methods: Post-menopausal patients with HR-positive metastatic breast cancer were randomized to anastrozole with or without concurrent fulvestrant.

To address this issue, we began the DATA study to assess different durations of anastrozole therapy after tamoxifen.

In these, TTR was longer for anastrozole than for tamoxifen by a similar extent to that in the overall trial.

Methods: We performed a randomized, double-blind, placebo-controlled trial of anastrozole in patients with PAH who received background therapy at two centers.

Low ER or PgR or high HER-2 expression are associated with a high risk of recurrence with either anastrozole or tamoxifen.

CTS has little impact on the overall risk-to-benefit ratio for the use of anastrozole in postmenopausal women with early breast cancer.

Tamoxifen is effective and well tolerated, although the non-steroidal AIs, anastrozole and letrozole, are more effective treatments for advanced disease than tamoxifen.

We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.

Interpretation: Compared with tamoxifen, anastrozole treatment provided a significant improvement in breast cancer-free interval, mainly in women younger than 60 years of age.

The 2019 update includes those and adds a class of medications called aromatase inhibitors (including exemestane and anastrozole) to that list.

In a retrospective analysis of the combined data from these trials, mean duration of response was significantly greater for fulvestrant compared with anastrozole.

Conclusions: Fewer endometrial abnormalities occurred during 2 years treatment with anastrozole compared with tamoxifen although statistical significance was not reached in this sub-protocol analysis.